Migraine remains one of the most common and disabling neurological conditions in the UK, affecting around ten million people. For decades, treatment options have offered limited relief to many patients, particularly those for whom traditional therapies are ineffective or unsuitable. The recent introduction of rimegepant, marketed in the UK as Vydura by Pfizer, marks a significant step forward in the treatment and prevention of migraine.
First oral medication of its kind
Rimegepant is the first oral medication licensed in the UK for both the acute treatment of migraine attacks and for preventive use. Developed by Biohaven Pharmaceuticals, it belongs to a new class of drugs called CGRP receptor antagonists. These drugs target the calcitonin gene-related peptide (CGRP), a protein that plays a key role in migraine attacks by promoting inflammation and dilating blood vessels in the brain.
Unlike older treatments such as triptans, which constrict blood vessels and may be unsuitable for people with cardiovascular conditions, rimegepant blocks the CGRP receptor without affecting blood flow. This gives it a broader safety profile and makes it accessible to a wider range of patients. It is administered as a fast-dissolving oral tablet, taken at the onset of an attack or every other day for preventive care.
Promising clinical trials
Clinical trials have demonstrated the efficacy of rimegepant in both contexts. For acute use, a significant number of patients experienced pain relief within two hours, including freedom from their most bothersome migraine symptoms. In preventive studies, those taking rimegepant every other day had fewer monthly migraine days compared to those given a placebo. This dual-purpose approach offers new flexibility for patients and clinicians in managing an unpredictable condition.
Migraine is more than just a headache, it can cause visual disturbances, nausea, fatigue, and severe sensitivity to light and sound. These symptoms can disrupt work, education, and social life, placing a significant burden on individuals and the healthcare system. According to the NHS, migraine is one of the most frequent causes of disability among working-age adults. Improving treatment options is therefore not only a clinical priority, but also a social and economic one.
Following approval from the Medicines and Healthcare products Regulatory Agency (MHRA), rimegepant was appraised by the National Institute for Health and Care Excellence (NICE). In final guidance, NICE recommended the drug for NHS use in England and Wales for adults who have tried at least two other acute treatments that failed. This decision
reflects a growing openness to introducing advanced therapies when supported by evidence of effectiveness and cost-efficiency.
Shift in the life sciences sector
The arrival of rimegepant in the UK signals a shift in how the life sciences sector is approaching common, chronic conditions. While much attention is often given to rare diseases or cancer innovations, migraine affects a far larger segment of the population and has been historically underserved. The development and approval of CGRP antagonists like rimegepant represent a new phase of progress in migraine care, with more targeted treatments reaching patients.
Dr Tony Wood, Chief Scientific Officer at GSK, recently remarked on the UK’s broader research momentum: “We welcome the government’s Life Sciences Sector Plan – in particular, the reforms to incentivise more UK clinical trials… These changes can bring unique competitive advantages to the country and make the UK a leader in future life sciences research.”
Will change lives of those who suffer from migraines
For the life sciences industry, rimegepant is a compelling example of how innovation, investment, and clinical need can align to deliver meaningful change. As more patients gain access to this treatment, the expectation is that it will not only improve health outcomes but also reduce reliance on emergency care and improve day-to-day quality of life for people living with migraine.
